Talk:CYP2D6

From Wikipedia, the free encyclopedia

	MCB Portal This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme.
Start	This article has been rated as start-Class on the assessment scale.
Low	This article is on a subject of low-importance within molecular and cellular biology.
Article Grading: The article has been rated for quality and/or importance but has no comments yet. If appropriate, please review the article and then leave comments here to identify the strengths and weaknesses of the article and what work it will need.

I have heard that CYP2D6 is a non-inducible enzyme in human hepatocytes. This article states otherwise. Does anyone have any specific references that may indicate one way or the other?

I've seen some speculation about that too, but here are a few references: PMID 15001973, PMID 12354285 -Techelf 11:55, 12 May 2005 (UTC)

[edit] Tamoxifen

This article seems a bit in need of updating to me! I'm just learning about this stuff, but according to the Genelex website at www.healthanddna.com, there are FOUR types of CYP2D6 metabolizers, not three - the intermediate metabolizer is missing from this article. In addition, the substrate table is out of date, as it no longer accurately reflects the Flockhart table - for example, on the Flockhart table buproprion is now listed as a strong inhibitor. Furthermore, CYP2D6 is very important to the metabolism of tamoxifen and that story deserves a paragraph in it's own right.

However, I'm not a genetecist, just someone who had breast cancer who has been tested for the CYP2D6 metabolism, found to be an intermediate metabolizer, and who is trying to figure out what that means for taking tamoxifen, as there's no sense in taking something I can't metabolize. There are some leads on my cancer blog, www.imaginebrightfutures.wordpress.com, but other than that, I'm still not at the place where I feel comfortable writing this stuff up, I just wanted to note that it needs to be done! To all who contributed to this article so far, it's a great start! —Preceding unsigned comment added by Aunt Amanda (talk • contribs) 04:06, 5 January 2008 (UTC)

If you look carefully, the article defines an extensive metaboliser as one who has normal or reduced activity. If you're an intermediate metaboliser, I would assume you can metabolize tamoxifen fine. Since tamoxifen is a prodrug and must undergo metabolism before being active, it would be beneficial for a patient taking tamoxifen to be able to metabolize it more readily. A patient taking tamoxifen should avoid taking medications, such as SSRI's, which compete with tamoxifen for CYP2D6 or medications which inhibit CYP2D6 activity. It might also be a good idea for low metabolizers taking tamoxifen to try to induce CYP2D6 activity. With that said, I'm a chemist and not an MD, so don't take my word as medical advice. This isozyme is of particular interest to me. I'll attempt to incorporate your suggestions in any updates I make to the article, however, I think a lot of your questions are answered in the article on tamoxifen. --Jmcclare (talk) 03:44, 10 April 2008 (UTC)